Skip to main content
SP5007,785.76-0.17%DOW53,732.41-0.20%NASDAQ26,729.16-0.28%BTC$62,941.00-0.62%ETH$1,878.51-0.33%GOLD$4,430.00+0.22%OIL$82.38+1.39%
Smart Investors Daily
Sign InSign Up Free
FU

NASDAQ · FULC

Fulcrum Therapeutics, Inc.

Healthcare · Biotechnology

$3.71

Up+$0.03 (+0.81%)

Updated Aug 14, 2026, 8:16 PM

SID Score

4.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
692.63M
P/E ratio
-11.27
Dividend yield
0.00%
52-week range
$2.83 – $8.37
Volume
1.36M
Avg. volume
1.17M

Price performance

FULC price history

1M range · 21 trading sessions · Daily adjusted prices

FULC closed at $3.71 after 21 trading sessions, up 6.00% for the selected period.

Last close
$3.71
Period change
+6.00%
Period low
$3.50
Period high
$3.89
Daily close
View OHLC price history
FULC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 13, 2026$3.75$3.76$3.64$3.711.36M
Aug 12, 2026$3.70$3.74$3.615$3.72901.4K
Aug 11, 2026$3.77$3.775$3.655$3.69804.12K
Aug 10, 2026$3.85$3.87$3.74$3.751.12M
Aug 7, 2026$3.83$3.91$3.77$3.891.46M
Aug 6, 2026$3.76$3.815$3.685$3.771.04M
Aug 5, 2026$3.80$3.82$3.72$3.771.25M
Aug 4, 2026$3.73$3.835$3.695$3.802.35M
Aug 3, 2026$3.63$3.725$3.544$3.712.26M
Jul 31, 2026$3.72$3.73$3.47$3.583.53M
Jul 30, 2026$3.60$3.75$3.58$3.721.15M
Jul 29, 2026$3.69$3.76$3.59$3.621.11M
Jul 28, 2026$3.73$3.76$3.62$3.721.2M
Jul 27, 2026$3.76$3.81$3.70$3.73589.76K
Jul 24, 2026$3.78$3.81$3.70$3.72572.86K
Jul 23, 2026$3.64$3.78$3.625$3.76830.09K
Jul 22, 2026$3.69$3.735$3.61$3.701.42M
Jul 21, 2026$3.62$3.745$3.62$3.681.53M
Jul 20, 2026$3.71$3.775$3.58$3.62822.2K
Jul 17, 2026$3.47$3.785$3.46$3.652.3M
Jul 16, 2026$3.77$3.7759$3.45$3.502.72M

Latest FULC news

The latest Smart Investors Daily articles mentioning FULC.

Stock researchCompany · Overview

FULC research

Overview

Company profile and research snapshot.

Company profile

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$20.71
Implied upside
—
Analysts
15
FULC recent ratings
DateFirmRatingTarget
Jun 3, 2026JP MorganUnderweight—
Jun 2, 2026Piper SandlerUnderweight—
Jun 2, 2026StifelHold—
Jun 2, 2026Truist SecuritiesHold—
Jun 2, 2026Leerink PartnersMarket Perform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 5, 2026

Fulcrum Therapeutics (FULC) Stock Sees Modest Fair Value Lift After Pociredir Exit

The updated analyst framework for Fulcrum Therapeutics lifts the Fair Value estimate from US$5.43 to US$5.83 per share. This shift in price target sits against a backdrop of sharply changed Street commentary after the decision to discontinue pociredir, with more focus on cash, restructuring and the ongoing review of options than on late stage development potential. Read on to see how this evolving narrative could matter for your own view on Fulcrum Therapeutics and how to track the next set...

Benzinga · Jun 4, 2026

UPDATED: Fulcrum Therapeutics Launches Restructuring Plan Following Discontinuation Of Pociredir For Sickle Cell Disease, Cutting Workforce By 85% From 57 To 9 Employees And Recording ~$4.2M In Restructuring Charges

On May 31, 2026, the board of directors of Fulcrum Therapeutics, Inc., or Fulcrum, approved a restructuring plan to significantly reduce Fulcrum’s operating expenses and preserve capital following the discontinuation of development of pociredir for the treatment of sickle cell disease, or SCD.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By